News coverage about Altimmune (NYSE:ALT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Altimmune earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.0130369515855 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, Dawson James reissued a “buy” rating on shares of Altimmune in a report on Tuesday, May 29th.
Shares of ALT stock traded up $0.01 during mid-day trading on Thursday, reaching $0.32. The company’s stock had a trading volume of 165,700 shares, compared to its average volume of 656,297. Altimmune has a 1-year low of $0.25 and a 1-year high of $3.16.
Altimmune (NYSE:ALT) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $3.01 million.
Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.
Recommended Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.